

# UCLA

## UCLA Previously Published Works

### Title

Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

### Permalink

<https://escholarship.org/uc/item/1r57187f>

### Journal

Advances in Therapy, 34(7)

### ISSN

0741-238X

### Authors

Adsit, Sandra  
Zaldivar, Enrique Rivas  
Sofen, Howard  
[et al.](#)

### Publication Date

2017-07-01

### DOI

10.1007/s12325-017-0563-2

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

ERRATUM

## Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Sandra Adsit · Enrique Rivas Zaldivar · Howard Sofen ·  
Ignacio Dei-Cas · César Maldonado-García · Elkin O. Peñaranda ·  
Luís Puig · Xiangyi Meng · Todd Fox · Adriana Guana

Published online: June 6, 2017  
© The Author(s) 2017. This article is an open access publication

Erratum to: Adv Ther  
DOI 10.1007/s12325-017-0521-z

Unfortunately, the given name and family name of the co-author Dr. César Maldonado García were incorrectly published in the original publication. The correct given name and family name should read as ‘César’ and ‘Maldonado-García’, respectively.

Also Dr. César Maldonado-García’s affiliation should read as follows:

C. Maldonado-García  
Centro Dermatológico “Dr. Ladislao de la Pascua”, Mexico City, Mexico

The original article has been corrected.

**Open Access.** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

---

The online version of the original article can be found under doi:[10.1007/s12325-017-0521-z](https://doi.org/10.1007/s12325-017-0521-z).

---

S. Adsit (✉)  
TCR Medical Corporation, San Diego, CA, USA  
e-mail: sadsit@therapeuticsinc.com

E. R. Zaldivar  
Dermos, Guatemala City, Guatemala

H. Sofen  
UCLA School of Medicine, Los Angeles, CA, USA

I. Dei-Cas  
Halitus, Buenos Aires, Argentina

C. Maldonado-García  
Centro Dermatológico “Dr. Ladislao de la Pascua”,  
Mexico City, Mexico

E. O. Peñaranda  
Riesgo de Fractura S.A., Bogota, Colombia

L. Puig  
Hospital de la Santa Creu i Sant Pau, Universitat  
Autònoma de Barcelona, Barcelona, Spain

X. Meng · A. Guana  
Novartis Pharmaceuticals Corporation,  
East Hanover, NJ, USA

T. Fox  
Novartis Pharma AG, Basel, Switzerland